Federal Life Insurance Company Selects DXC Technology to Enhance Policy Buying Experience for Customers and Agents
28.4.2020 16:00:00 EEST | Business Wire | Press release
Federal Life Insurance Company, based in Riverwoods, IL just northwest of Chicago, has gone live with DXC Assure for Life and Wealth to enhance the policy buying experience for their customers and agents, streamline key processes, and drive business growth. DXC’s solution is built on a scalable, cloud-based architecture, implemented on Amazon Web Services (AWS), and provided to Federal Life on an “as-a-Service” basis.
DXC Technology’s end-to-end insurance management solution streamlines new business acquisition for Federal Life by guiding producers through the data-gathering process, ensuring that all necessary information is collected at the point of sale. Information is automatically captured and submitted through a paperless, self-service process for immediate consideration. Additionally, Federal Life now benefits from straight-through processing of online policy requests with electronic signatures (e-signatures).
“Accelerating the application process and providing a superior customer experience that meets ― and exceeds ― our customers’ expectations is of critical importance to Federal Life Insurance Company,” said Bill Austin, CEO, Federal Life Group, Inc. “DXC’s platform, backed by DXC’s strong life and annuities expertise, will support us in providing a rich, easy-to-use online application experience on any device, and give us the flexibility to adapt to evolving customer needs quickly and cost effectively.”
DXC Assure for Life and Wealth encompasses electronic applications, forms management, policy administration, flexible product configuration, claims management and more. It helps insurers transform and reimagine customer-facing applications to deliver a high-quality user experience accessible on any device.
Federal Life, a longtime DXC customer, has plans to bring current and future products to DXC Assure for Life and Wealth deployed on AWS, leveraging it as a foundation to modernize the legacy IT landscape with new digital cloud-based capabilities.
“We are proud to continue our collaboration with Federal Life as it builds its digital business,” said Phil Ratcliff, vice president and general manager, Global Insurance, DXC Technology. “DXC Assure for Life and Wealth addresses key challenges that insurers are facing in today’s fast-changing market, and it will enable Federal Life to transform its business processes while improving new business speed-to-issue by streamlining and accelerating policy submission.”
DXC’s electronic application capability is a key component of DXC Assure for Life and Wealth. The overall solution accommodates contemporary life and wealth products, including term, traditional, variable and equity index life and annuity products. Business-focused API services dramatically simplify integration with customer, agent, third-party services and corporate systems. DXC Assure for Life and Wealth is an integrated solution that can be deployed in whole or in parts, enabling carriers to get into production quickly with only the components they need now.
DXC has served the global insurance industry for over 40 years, with more than 1,900 clients, active client communities and millions of policies administered on DXC’s life and annuity software and in business process services and solutions operations.
For more information on DXC Assure for Life and Wealth, click here.
About Federal Life Group, Inc.
Federal Life Group, Inc. (OTCMKTS: FLFG) is the parent of Federal Life Insurance Company (FLIC), an independently operated provider of quality life insurance and annuity products, incorporated in 1899. FLIC is headquartered in Riverwoods, Illinois, a suburb approximately thirty miles north of Chicago. FLIC is proud of its longstanding tradition of financial strength and stability. For more information, go to www.federallife.com.
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200428005011/en/
Contact information
Dana Greenstein, Corporate Media Relations, +1.914.607.7631, dgreenstein@dxc.com
Shailesh Murali, M&A and Investor Relations, +1.703.245.9700, shailesh.murali@dxc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom